{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:24:29Z","timestamp":1784582669505,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Ministry of Science, Technological Development and Innovation of the Republic of Serbia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05781-1","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T13:02:12Z","timestamp":1715086932000},"page":"2865-2875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Inflammation mediated angiogenesis in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3977-2780","authenticated-orcid":false,"given":"Olivera","family":"Mitrovi\u0107-Ajti\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilija","family":"\u017divkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijana","family":"Suboti\u010dki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Dikli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragoslava","family":"\u0110iki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Vukoti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Dragojevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojin","family":"Vukovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Anti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan P.","family":"\u010coki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"5781_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2018.00683","volume":"9","author":"W Darwiche","year":"2018","unstructured":"Darwiche W, Gubler B, Marolleau JP (2018) Ghamlouch H (2018) Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues from a Functional Perspective. Front Immunol 9:683. https:\/\/doi.org\/10.3389\/fimmu.2018.00683","journal-title":"Front Immunol"},{"issue":"4","key":"5781_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","volume":"126","author":"P Strati","year":"2015","unstructured":"Strati P, Shanafelt TD (2015) Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126(4):454\u2013462. https:\/\/doi.org\/10.1182\/blood-2015-02-585059","journal-title":"Blood"},{"key":"5781_CR3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3389\/fonc.2019.01399","volume":"9","author":"D Aguilar-Cazares","year":"2019","unstructured":"Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, Lopez-Camarillo C, Hernadez de la Cruz ON, Lopez-Gonzalez JS (2019) Contribution of Angiogenesis to Inflammation and Cancer. Front Oncol 9:1399. https:\/\/doi.org\/10.3389\/fonc.2019.01399","journal-title":"Front Oncol"},{"issue":"13","key":"5781_CR4","doi-asserted-by":"publisher","first-page":"6952","DOI":"10.3390\/ijms23136952","volume":"23","author":"O Mitrovi\u0107Ajti\u0107","year":"2022","unstructured":"Mitrovi\u0107Ajti\u0107 O, Suboti\u010dki T, Dikli\u0107 M, \u0110iki\u0107 D, Vukoti\u0107 M, Dragojevi\u0107 T, \u017divkovi\u0107 E, Anti\u0107 D, \u010coki\u0107 V (2022) Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia. Int J Mol Sci 23(13):6952. https:\/\/doi.org\/10.3390\/ijms23136952","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5781_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5582\/irdr.2015.01048","volume":"5","author":"Y Han","year":"2016","unstructured":"Han Y, Wang X, Wang B, Jiang G (2016) The progress of angiogenic factors in the development of leukemias. Intractable Rare Dis Res 5(1):6\u201316. https:\/\/doi.org\/10.5582\/irdr.2015.01048","journal-title":"Intractable Rare Dis Res"},{"key":"5781_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fcell.2020.00584","volume":"8","author":"C Montemagno","year":"2020","unstructured":"Montemagno C, Pag\u00e8s G (2020) Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Front Cell Dev Biol 8:584. https:\/\/doi.org\/10.3389\/fcell.2020.00584","journal-title":"Front Cell Dev Biol"},{"key":"5781_CR7","first-page":"2898","volume":"60","author":"J Adams","year":"2000","unstructured":"Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE (2000) Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60:2898\u20132905","journal-title":"Cancer Res"},{"key":"5781_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.leu.2402467","volume":"16","author":"NE Kay","year":"2002","unstructured":"Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF (2002) B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16:911\u2013919. https:\/\/doi.org\/10.1038\/sj.leu.2402467","journal-title":"Leukemia"},{"issue":"4","key":"5781_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3324\/haematol.2019.217430","volume":"105","author":"V Griggio","year":"2020","unstructured":"Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Bo MD, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omed\u00e8 P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Fo\u00e0 R, Massaia M, Boccadoro M, Coscia M (2020) HIF-1\u03b1 is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica 105(4):1042\u20131054. https:\/\/doi.org\/10.3324\/haematol.2019.217430","journal-title":"Haematologica"},{"issue":"22","key":"5781_CR10","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1182\/blood-2008-10-185686","volume":"113","author":"AK Ghosh","year":"2009","unstructured":"Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu CG, Calin GA, Croce CM, Chan DA, Giaccia AJ, Secreto C, Wellik LE, Lee YK, Mukhopadhyay D, Kay NE (2009) Aberrant regulation of pVHL levels by microRNA promotes the HIF\/VEGF axis in CLL B cells. Blood 113(22):5568\u20135574. https:\/\/doi.org\/10.1182\/blood-2008-10-185686","journal-title":"Blood"},{"issue":"7","key":"5781_CR11","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.3390\/ijms22073765","volume":"22","author":"F Lopes-Coelho","year":"2021","unstructured":"Lopes-Coelho F, Martins F, Pereira SA, Serpa J (2021) Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int J Mol Sci 22(7):3765. https:\/\/doi.org\/10.3390\/ijms22073765","journal-title":"Int J Mol Sci"},{"key":"5781_CR12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/nrc925","volume":"2","author":"S Rafii","year":"2002","unstructured":"Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826\u2013835. https:\/\/doi.org\/10.1038\/nrc925","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"5781_CR13","doi-asserted-by":"publisher","first-page":"6671","DOI":"10.3390\/ijms22136671","volume":"22","author":"T Suboti\u010dki","year":"2021","unstructured":"Suboti\u010dki T, Mitrovi\u0107Ajti\u0107 O, \u017divkovi\u0107 E, Dikli\u0107 M, \u0110iki\u0107 D, To\u0161i\u0107 M, Beleslin-\u010coki\u0107 B, Dragojevi\u0107 T, Goti\u0107 M, Santibanez JF, \u010coki\u0107 V (2021) VEGF Regulation of Angiogenic Factors via Inflammatory Signaling in Myeloproliferative Neoplasms. Int J Mol Sci 22(13):6671. https:\/\/doi.org\/10.3390\/ijms22136671","journal-title":"Int J Mol Sci"},{"key":"5781_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2018.00683","volume":"9","author":"W Darwiche","year":"2018","unstructured":"Darwiche W, Gubler B, Marolleau JP, Ghamlouch H (2018) Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective. Front Immunol 9:683. https:\/\/doi.org\/10.3389\/fimmu.2018.00683","journal-title":"Front Immunol"},{"key":"5781_CR15","doi-asserted-by":"publisher","first-page":"869242","DOI":"10.1155\/2015\/869242","volume":"2015","author":"G Hoermann","year":"2015","unstructured":"Hoermann G, Greiner G, Valent P (2015) Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediat Inflamm 2015:869242. https:\/\/doi.org\/10.1155\/2015\/869242","journal-title":"Mediat Inflamm"},{"key":"5781_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.leukres.2018.01.006","volume":"66","author":"F Zhu","year":"2018","unstructured":"Zhu F, McCaw L, Spaner DE, Gorczynski RM (2018) Targeting the IL-17\/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo\/in vitro. Leuk Res 66:28\u201338. https:\/\/doi.org\/10.1016\/j.leukres.2018.01.006","journal-title":"Leuk Res"},{"issue":"3","key":"5781_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.leukres.2009.06.023","volume":"34","author":"R Maffei","year":"2010","unstructured":"Maffei R, Martinelli S, Castelli I, Santachiara R, Zucchini P, Fontana M, Fiorcari S, Bonacorsi G, Ilariucci F, Torelli G, Marasca R (2010) Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia derived Ang2 and VEGF. Leuk Res 34(3):312\u2013321. https:\/\/doi.org\/10.1016\/j.leukres.2009.06.023","journal-title":"Leuk Res"},{"key":"5781_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1746-1596-3-16","volume":"3","author":"JL Frater","year":"2008","unstructured":"Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC (2008) Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. Diagn Pathol 3:16. https:\/\/doi.org\/10.1186\/1746-1596-3-16","journal-title":"Diagn Pathol"},{"key":"5781_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000046611","volume":"106","author":"D Ribatti","year":"2001","unstructured":"Ribatti D, Vacca A, De Falco G, Ria R, Roncali L, Damacco F (2001) Role of hematopoietic growth factors in angiogenesis. Acta Haematol 106:157\u2013161. https:\/\/doi.org\/10.1159\/000046611","journal-title":"Acta Haematol"},{"issue":"48","key":"5781_CR20","doi-asserted-by":"publisher","first-page":"78269","DOI":"10.18632\/oncotarget.13412","volume":"7","author":"NE Kay","year":"2016","unstructured":"Kay NE, Strati P, LaPlant BR, Leis JF, Nikcevich D, Call TG, Pettinger AM, Lesnick CE, Hanson CA, Shanafelt TD (2016) A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. Oncotarget 7(48):78269\u201378280. https:\/\/doi.org\/10.18632\/oncotarget.13412","journal-title":"Oncotarget"},{"issue":"8","key":"5781_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s43018-021-00216-6","volume":"2","author":"J Lu","year":"2021","unstructured":"Lu J, Cannizzaro E, Meier-Abt F, Scheinost S, Bruch PM, Giles HA, L\u00fctge A, H\u00fcllein J, Wagner L, Giacopelli B, Nadeu F, Delgado J, Campo E, Mangolini M, Ringshausen I, B\u00f6ttcher M, Mougiakakos D, Jacobs A, Bodenmiller B, Dietrich S, Oakes CC, Zenz T, Huber W (2021) Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. Nat Cancer 2(8):853\u2013864. https:\/\/doi.org\/10.1038\/s43018-021-00216-6","journal-title":"Nat Cancer"},{"key":"5781_CR22","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/cncr.25005","volume":"116","author":"CS Zent","year":"2010","unstructured":"Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, Witzig TE (2010) The treatment of recurrent\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 116:2201\u20132207. https:\/\/doi.org\/10.1002\/cncr.25005","journal-title":"Cancer"},{"key":"5781_CR23","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1182\/blood-2014-11-610329","volume":"25","author":"MD Blunt","year":"2015","unstructured":"Blunt MD, Carter MJ, Larrayoz M, Smith LD, Aguilar-Hernandez M, Cox KL, Tipton T, Reynolds M, Murphy S, Lemm E, Dias S, Duncombe A, Strefford JC, Johnson PW, Forconi F, Stevenson FK, Packham G, Cragg MS, Steele AJ (2015) The PI3K\/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E\u03bc-TCL1 mouse model. Blood 25:4032\u20134041. https:\/\/doi.org\/10.1182\/blood-2014-11-610329","journal-title":"Blood"},{"issue":"13","key":"5781_CR24","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1182\/blood.2019001366","volume":"134","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ (2019) Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-\u03baB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood 134(13):1084\u20131094. https:\/\/doi.org\/10.1182\/blood.2019001366","journal-title":"Blood"},{"issue":"4","key":"5781_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/sj.leu.2403631","volume":"19","author":"M Farahani","year":"2005","unstructured":"Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, Cawley JC, Zuzel M, Chen H (2005) Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 19(4):524\u2013530. https:\/\/doi.org\/10.1038\/sj.leu.2403631","journal-title":"Leukemia"},{"key":"5781_CR26","doi-asserted-by":"publisher","unstructured":"Okumura N, Yoshida H, Kitagishi Y, Murakami M, Nishimura Y, Matsuda S (2012) PI3K\/AKT\/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis. Adv Hematol 843085. https:\/\/doi.org\/10.1155\/2012\/843085","DOI":"10.1155\/2012\/843085"},{"issue":"2","key":"5781_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2008.11.012","volume":"280","author":"L Ellis","year":"2009","unstructured":"Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280(2):145\u2013153. https:\/\/doi.org\/10.1016\/j.canlet.2008.11.012","journal-title":"Cancer Lett"},{"issue":"2","key":"5781_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10456-011-9201-9","volume":"14","author":"Q Li","year":"2011","unstructured":"Li Q, Michaud M, Canosa S, Kuo A, Madri JA (2011) GSK-3\u03b2: a signaling pathway node modulating neural stem cell and endothelial cell interactions. Angiogenesis 14(2):173\u2013185. https:\/\/doi.org\/10.1007\/s10456-011-9201-9","journal-title":"Angiogenesis"},{"issue":"10","key":"5781_CR29","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1590\/1806-9282.20220260","volume":"68","author":"M Khodashenas","year":"1992","unstructured":"Khodashenas M, Rajabian A, Attaranzadeh A, Lavi Arab F, Allahyari N (1992) Allahyari A (2022) Evaluation of cytokine levels as possible predicting elements in patients with chronic lymphocytic leukemia. Rev Assoc Med Bras 68(10):1364\u20131368. https:\/\/doi.org\/10.1590\/1806-9282.20220260","journal-title":"Rev Assoc Med Bras"},{"issue":"3","key":"5781_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3324\/haematol.2013.098442","volume":"99","author":"S Bibi","year":"2014","unstructured":"Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, Tchertanov L, Moriggl R, Valent P, Arock M (2014) Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica 99(3):417\u2013429. https:\/\/doi.org\/10.3324\/haematol.2013.098442","journal-title":"Haematologica"},{"key":"5781_CR31","doi-asserted-by":"publisher","unstructured":"Matvieieva AS, Kovalevska LM, Ivanivska TS, Klein E, Kashuba EV (2019) The STAT5 transcription factor in B-cells of patients with chronic lymphocytic leukemia. Biopolym Cell 30\u201338. https:\/\/doi.org\/10.7124\/bc.000993","DOI":"10.7124\/bc.000993"},{"issue":"3","key":"5781_CR32","doi-asserted-by":"publisher","first-page":"101042831769455","DOI":"10.1177\/1010428317694551","volume":"39","author":"M Witkowska","year":"2017","unstructured":"Witkowska M, Majchrzak A, Cebula-Obrzut B, Wawrzyniak E, Robak T, Smolewski P (2017) The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. Tumour Biol 39(3):1010428317694551. https:\/\/doi.org\/10.1177\/1010428317694551","journal-title":"Tumour Biol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05781-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05781-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05781-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:07:10Z","timestamp":1722060430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05781-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5781"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05781-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the University Clinical Centre of Serbia, Belgrade (decision number 187\/4) and the Ethics Committee of the Institute for Medical Research, Belgrade (decision number EO 117\/2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board Statement"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}